Episode Details
Back to Episodes
Apogee will have at lest four key trial readouts for its half-life optimized IL-13 program next year, including monotherapy trials and in combination with OX40L and TSLP.
Published 10 months ago
Description
CEO Michael Henderson walks us through what will be a busy year for the company.